Analysts Set ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) PT at $79.00

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have been given an average recommendation of “Buy” by the ten brokerages that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $79.78.

ANIP has been the topic of several analyst reports. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday. They set an “overweight” rating and a $85.00 price objective for the company. Finally, Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th.

ANI Pharmaceuticals Trading Up 1.7 %

ANIP stock opened at $62.49 on Wednesday. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm’s fifty day simple moving average is $58.26 and its two-hundred day simple moving average is $58.13.

Insiders Place Their Bets

In other news, VP Meredith Cook sold 400 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the transaction, the vice president now owns 80,545 shares of the company’s stock, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Stephen P. Carey sold 7,500 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the transaction, the chief financial officer now owns 154,468 shares in the company, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,700 shares of company stock worth $610,201 in the last ninety days. 12.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several large investors have recently modified their holdings of the business. JPMorgan Chase & Co. raised its stake in ANI Pharmaceuticals by 159.3% in the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company’s stock worth $33,101,000 after buying an additional 340,854 shares in the last quarter. Global Alpha Capital Management Ltd. raised its position in shares of ANI Pharmaceuticals by 1.8% in the 3rd quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its stake in shares of ANI Pharmaceuticals by 17.6% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock worth $13,731,000 after purchasing an additional 34,416 shares during the last quarter. Thrivent Financial for Lutherans boosted its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after purchasing an additional 299 shares in the last quarter. Finally, Mizuho Markets Americas LLC purchased a new position in ANI Pharmaceuticals in the third quarter valued at about $11,670,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.